A combination of ORPATHYS plus TAGRISSO improved outcomes for patients with first-line EGFR-mutated lung cancer with MET overexpression, according to Phase III SANOVO trial results presented at the ESMO Congress 2026 in Madrid on October 26, 2026.
According to HUTCHMED, the trial enrolled 326 patients in China with locally advanced or metastatic EGFR-mutated non-small cell lung cancer and MET overexpression, comparing savolitinib plus osimertinib against osimertinib alone. In the intention-to-treat population, median progression-free survival was 24.9 months with the combination versus 13.8 months with TAGRISSO alone, a hazard ratio of 0.56, meaning a 44 percent lower risk of progression or death.
The benefit was larger in patients with high MET overexpression, according to BioSpace, which reported the same results on October 26, 2026: median progression-free survival of 24.8 months versus 11.1 months, a hazard ratio of 0.45. Median overall survival was 44.5 months versus 34.9 months, with 67.4 percent versus 47.4 percent of patients alive at three years.
Treatment discontinuation due to adverse events was 14.8 percent in the combination arm, according to HUTCHMED. The company plans a supplemental New Drug Application in China for this first-line setting, following the presentation as a Proffered Paper at ESMO, abstract LBA69.
These are trial results in a specific patient population, not a treatment recommendation for individual patients. What happens next is regulatory review in China and further analysis of the data, as oncologists assess how the combination fits alongside existing first-line options for EGFR-mutated lung cancer.
Image: Edelhart Kempeneers, public domain, via Wikimedia Commons